{"id":"https://openalex.org/W1990376166","doi":"https://doi.org/10.1007/s10549-008-0020-7","title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","display_name":"Analysis of dermatologic events in patients with cancer treated with lapatinib","publication_year":2008,"publication_date":"2008-07-03","ids":{"openalex":"https://openalex.org/W1990376166","doi":"https://doi.org/10.1007/s10549-008-0020-7","mag":"1990376166","pmid":"https://pubmed.ncbi.nlm.nih.gov/18600445"},"language":"en","primary_location":{"id":"doi:10.1007/s10549-008-0020-7","doi":"https://doi.org/10.1007/s10549-008-0020-7","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10549-008-0020-7","pdf_url":null,"source":{"id":"https://openalex.org/S142211178","display_name":"Breast Cancer Research and Treatment","issn_l":"0167-6806","issn":["0167-6806","1573-7217"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Breast Cancer Research and Treatment","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002599922","display_name":"Mario E. Lacouture","orcid":"https://orcid.org/0000-0002-4818-3710","observed_orcids":["https://orcid.org/0000-0002-4818-3710"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"M. E. Lacouture","raw_affiliation_strings":["Department of Dermatology, Northwestern University, 676 North St. Claire Street, Suite 1600, Chicago, IL 60611-2941, USA. m-lacouture@northwestern.edu","Northwestern University****"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Northwestern University, 676 North St. Claire Street, Suite 1600, Chicago, IL 60611-2941, USA. m-lacouture@northwestern.edu","institution_ids":["https://openalex.org/I111979921"]},{"raw_affiliation_string":"Northwestern University****","institution_ids":["https://openalex.org/I111979921"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002140942","display_name":"S. Laabs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. M. Laabs","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048598383","display_name":"Maria T. Koehler","orcid":"https://orcid.org/0000-0002-4477-9621","observed_orcids":["https://orcid.org/0000-0002-4477-9621"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. Koehler","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019786170","display_name":"Robert William Sweetman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"R. W. Sweetman","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069141898","display_name":"Alaknanda J. Preston","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"A. J. Preston","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105140867","display_name":"Angelo Di Leo","orcid":"https://orcid.org/0000-0002-3665-9056","observed_orcids":["https://orcid.org/0000-0002-3665-9056"]},"institutions":[{"id":"https://openalex.org/I4210109982","display_name":"Fondazione Sandro Pitigliani","ror":"https://ror.org/017rmsx09","country_code":"IT","type":"other","lineage":["https://openalex.org/I4210109982"]},{"id":"https://openalex.org/I4210166882","display_name":"Hospital of Prato","ror":"https://ror.org/03gbp6p96","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210156494","https://openalex.org/I4210156604","https://openalex.org/I4210166882"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A. Di Leo","raw_affiliation_strings":["\u201cSandro Pitigliani\u201d Medical Oncology Unit, Prato, Italy","\u201cSandro Pitigliani\u201d Medical Oncology Unit"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u201cSandro Pitigliani\u201d Medical Oncology Unit, Prato, Italy","institution_ids":["https://openalex.org/I4210166882"]},{"raw_affiliation_string":"\u201cSandro Pitigliani\u201d Medical Oncology Unit","institution_ids":["https://openalex.org/I4210109982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049679970","display_name":"Henry G\u00f3mez","orcid":"https://orcid.org/0000-0002-3415-9701","observed_orcids":["https://orcid.org/0000-0002-3415-9701","https://orcid.org/0000-0003-2660-1843"]},"institutions":[{"id":"https://openalex.org/I4210123325","display_name":"Instituto Nacional de Enfermedades Neopl\u00e1sicas","ror":"https://ror.org/03674y156","country_code":"PE","type":"healthcare","lineage":["https://openalex.org/I4210123325"]}],"countries":["PE"],"is_corresponding":false,"raw_author_name":"H. L. Gomez","raw_affiliation_strings":["Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru","institution_ids":["https://openalex.org/I4210123325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110086988","display_name":"Vanessa Salazar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"V. M. Salazar","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089647963","display_name":"Julie Byrne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. A. Byrne","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007441935","display_name":"Kevin M. Koch","orcid":"https://orcid.org/0000-0003-4490-9761","observed_orcids":["https://orcid.org/0000-0003-4490-9761"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"K. M. Koch","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA","GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]},{"raw_affiliation_string":"GlaxoSmithKline","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113693457","display_name":"K. L. Blackwell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. L. Blackwell","raw_affiliation_strings":["Duke University Medical Center, Durham, NC, USA","Duke University Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC, USA","institution_ids":["https://openalex.org/I4210126298"]},{"raw_affiliation_string":"Duke University Medical Center","institution_ids":["https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5002599922"],"corresponding_institution_ids":["https://openalex.org/I111979921"],"apc_list":{"value":4190,"currency":"USD","value_usd":4190},"apc_paid":null,"fwci":11.9274,"has_fulltext":false,"cited_by_count":87,"citation_normalized_percentile":{"value":0.98962858,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"114","issue":"3","first_page":"485","last_page":"493"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":1.0},{"id":"https://openalex.org/keywords/dermatologic-adverse-events","display_name":"dermatologic adverse events","score":0.9229999780654907},{"id":"https://openalex.org/keywords/hand-foot-syndrome","display_name":"hand-foot syndrome","score":0.9049999713897705},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.921999990940094},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8190000057220459},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.6940000057220459},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.953000009059906},{"id":"https://openalex.org/keywords/metastatic-cancer","display_name":"metastatic cancer","score":0.7889999747276306},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9430000185966492},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.5989999771118164},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9328957796096802},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7166996598243713},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.631418764591217},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5290918350219727},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5092579126358032},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5043271780014038},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43940645456314087},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.18560877442359924}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077341","descriptor_name":"Lapatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s10549-008-0020-7","doi":"https://doi.org/10.1007/s10549-008-0020-7","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10549-008-0020-7","pdf_url":null,"source":{"id":"https://openalex.org/S142211178","display_name":"Breast Cancer Research and Treatment","issn_l":"0167-6806","issn":["0167-6806","1573-7217"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Breast Cancer Research and Treatment","raw_type":"journal-article"},{"id":"pmid:18600445","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18600445","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Breast cancer research and treatment","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5699999928474426,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320309475","display_name":"Northwestern University","ror":"https://ror.org/000e0be47"},{"id":"https://openalex.org/F4320333106","display_name":"Robert H. Lurie Comprehensive Cancer Center","ror":"https://ror.org/000e0be47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W54318999","https://openalex.org/W68492735","https://openalex.org/W1967054917","https://openalex.org/W1968151389","https://openalex.org/W1973060721","https://openalex.org/W1986432855","https://openalex.org/W1991915991","https://openalex.org/W1998085563","https://openalex.org/W2011513069","https://openalex.org/W2023575200","https://openalex.org/W2024145840","https://openalex.org/W2076418469","https://openalex.org/W2080255466","https://openalex.org/W2110444464","https://openalex.org/W2122859071","https://openalex.org/W2128307445","https://openalex.org/W2134610254","https://openalex.org/W2136404962","https://openalex.org/W2142752401","https://openalex.org/W2144648936","https://openalex.org/W2157036179","https://openalex.org/W2242921747","https://openalex.org/W2247329814","https://openalex.org/W2283620289","https://openalex.org/W2298684087","https://openalex.org/W2413914216","https://openalex.org/W3189240145"],"related_works":["https://openalex.org/W2096496632","https://openalex.org/W67104293","https://openalex.org/W3177344046","https://openalex.org/W2438623550","https://openalex.org/W2536106369","https://openalex.org/W4246334651","https://openalex.org/W2037195973","https://openalex.org/W2989121736","https://openalex.org/W2892677547","https://openalex.org/W2557359331"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}